Nureca Q1 FY27 results: revenue up about 18%, PAT jumps over 4x YoY

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

NURECA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.6%Reaction day

₹293.00

prior close

₹324.99

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.2%+5.8% vs market

Medical Equipment & Supplies peers, median of 11sector-1.5%+6.1% vs sector

On the reaction day the stock moved 5.8 pts more than Nifty Microcap 250 and 6.1 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-1.2

15m

-1.2

30m

-3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.6-1.2+5.8-1.5+6.1

Next day

+0.8-1.9+2.6-1.2+2.0

+3.9-1.4+5.4-2.0+6.0

+7.8-0.1+8.0-1.9+9.7

+6.5-1.4+7.9-1.4+7.9

+11.6-1.0+12.5-1.2+12.8

+16.7-0.4+17.2-0.5+17.3

15d

+16.1+3.2+13.0-1.6+17.8

+2.4+4.4-2.0-0.4+2.8

+15.7+4.6+11.1+0.1+15.6

+12.0-3.6+15.5-15.6+27.6

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 11Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Nureca reported strong Q1 FY27 results. Standalone revenue rose 17.7% YoY to Rs 403.96M from Rs 343.24M. Standalone PAT jumped to Rs 24.32M from Rs 5.52M, a roughly 4x rise. Consolidated revenue grew 18% to Rs 403.43M with PAT at Rs 30.67M versus Rs 8.13M. Margins expanded sharply versus a year ago and versus the loss-making Q4 FY26. Statutory auditor Singhi and Co gave an unmodified limited review opinion.

Likely market impact

Sharp recovery from Q4 FY26 losses with strong YoY PAT growth and margin expansion, positive signal for the stock.